Despite the downgrade, Novo Nordisk’s shares rose 4.4% at the European market open. However, the stock remains down 26% year-to-date, compared with a flat performance by its main US rival, Eli ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

Novo Nordisk NOVO.B6.64%increase; green up pointing triangle lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back sales of its ...

COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership positions in its U.S. business following ...

6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32 nd ...

LONDON/COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

With its Q1 2025 results on Wednesday, Novo Nordisk (NVO) lowered its full-year outlook, but its shares were rising in European trading after the pharma giant projected a sales recovery for its ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Novo Nordisk announced its decision to partner with digital health providers to streamline access to Wegovy after a U.S. shortage has eased. And Novo will offer direct-to-consumer access via its ...

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an oral version of its blockbuster weight loss drug Wegovy. The Danish drugmaker – which has its U.S ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.